Our co-founder and CSO Per Falholt is in San Jose this week for SynBioBeta.
On Monday, Per participated in a fantastic fireside chat organized by Boston Consulting Group (BCG) where he shared his perspective on ‘Breaking the cost barrier in Biomanufacturing’, alongside Christina Agapakis, Joshua Lachter, and John Cumbers.
This matched the discussions we and our guests had last week over the grand opening of our pilot plant facility. Establishing industrial manufacturing plants will be a crucial next step to unlock the potential of a mature industrially proven technology for production of proteins – in Europe and the world. This will have a real effect on the global supply of nutrition and material – as well as a real economical effect on technology exports, adjacent industries, workforce, IP development and continued tech and academic leadership in the region.
With our pilot plant, our strain technology and know-how, we help customers around the world to get from innovation to industrial scaling with industrially proven technology.
Further, we at 21st.BIO will support taking some of the most nutritious dairy proteins to market with our BLG and casein programs, to enable these bulk proteins to be produced at industrial level.
Now is the time that the right players in the industry join forces to build large-scale production facilities for protein production with precision fermentation in Europe and all other regions. It will take a consortium of the right players to build the first full-scale demonstration facility, as well as favorable solutions around funding and regulations, including financial support to strengthen off-take.
This is the next step to accelerate our journey towards a sustainable world, with more nutritious food and better materials made with biology.
